3Hu S. Interaction of nateglinide with KATP channel in β - cell underlies its unique insulinotropic action European Journal of pharmacology 2002;442: 163- 171.
4Hansen AMK, Christensen IT, Hansen JB et al. Differential Interactions of Nateglinide and Repaglinide on the Humanβ- cell Sulphonylurea Receptor 1 Diabetes 2002;51:2789-2795.
5Lebovitz HE. Oral antidiabetic Agent:2004 Med Clin N Am 2004 ;88 : 847 - 863.
6Novartis Pack Insert Starlix 2004; 1, 1.
7Anderson DM, Shelley S, Crick N. et al. NoEffect of the Novel Antidiabetic Agent Nateglinide on the Pharmcokinetics and Anticoagulant Propeties of Warfarin in Healthy Volunteers J Chin pharmacol2002 ;42 : 1358 - 1363.
二级参考文献5
1Sato Y,Nishikawa M,Shinkai H,et al.Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-(trans-4-isopropylcycohexyl)-carbonyl-D-phenylalanine(A-4166) , and its stimulatory effect on insulin secretion in animals[].Diabetes Research and Clinical Practice.1991
2Karara AH,Dunning BE,Mcleod JF.The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects[].Journal of Clinical Pharmacology.1999
3Hollander PA,Schwartz SL,Gadtlin MR,et al.Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes[].Diabetes Care.2001
4Keilson L,Mather S,Walter YH,et al.Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus[].The Journal of Clinical Endocrinology.2000
5Takesada H,Matsuda K,Ohtake R,et al.Structure determination of metabolites isolated from urine and bile administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent[].Bioorganic and Medicinal Chemistry.1996
